Abstract
Abciximab (ReoPro®, Centocor, Eli Lilly) is an IgG1k Fab anti-GPIIb/IIIa chimeric monoclonal antibody (mAb) approved by FDA in 1993, by Health Canada in 1996, and by TGA (NZ) in 2005. In Europe the product was approved in some countries (UK, RoI), and under specific concertation procedures, but did not receive the final clearance from EMEA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ReoPro® (Abciximab) BLA 97-0200/103575 medical review FDA Oct 1997
ReoPro® (Abciximab) Product Monograph. Eli Lilly Canada, Mar 2012
ReoPro® (Abciximab) Product Information Theory. Eur Heart J Eli Lilly/Janssen, Mar 2011
Califf RM (1997) The GUSTO trial and the open artery theory. Eur Heart J 18 (s):F2–F10
Askari AT, Lincoff AM (2002) GUSTO V: combination drug treatment of acute myocardial infarction. Clev Clin J Med 69:554–560
Hook KM, Bennett JS (2004) Glycoprotein IIa/IIIa antagonists. In: Antiplatelet agents. P Gresele et al (eds) Springer, pp 200–218
Simon DI, Xu H, Ortlepp S, Rogers C et al (1997) 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17:528–535
Mickelson JK, Ali MN, Kleiman NS et al (1999) Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 33:97–106
Marciniak SJ, Mascelli MA, Furman MI et al (2002) An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87:1020–1025
Kalra S, Bell MR, Rihal CS (2001) Alveolar hemorrhage as a complication of treatment with Abciximab. Chest 120:126–131
Curtis BR, Swyers J, Divgi A et al (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99:2054–2059
Tcheng JE, Kereiakes DJ, Lincoff AM et al (2001) Abciximab readministration. Results on the ReoPro readministration registry. Circulation 104:870–875
Applegate RJ, Sacrinty MT, Kutcher MA et al (2008) Off-label stent therapy. 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 51:607–614
Robinson M, Ginnelly L, Schulfer M et al (2002) A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIa antagonists. Health Technol Assessment 6: 1–171 (www.hta.ac.uk)
Author information
Authors and Affiliations
Corresponding author
1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Abciximab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_5
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)